After the subcutaneous administration of GLP-1, it could enter the brain by binding to bloodbrainbarrier-free organs such as the subfornical organ and the area postrema [43], or through the choroid plexus, which has a high density of GLP-1 receptors [17]
In research published in JAMA Neurology on April 7, UF researchers studied Medicare claims data of older adults with Type 2 diabetes to assess the association among glucagon-like peptide-1 receptor agonists, or GLP-1RAs, sodium-glucose cotransporter-2 inhibitors, or SGLT2is, and the risk of Alzheimers disease and related dementias
Cellular senescence and Alzheimer disease: the egg and the chicken scenario
The FDA and EMA have stated that the current data do not support a causal relationship
GLP-1 receptor agonists and appetite regulation
Alpha lipoic acid (ALA) In a 2021 interview with Bulletproof Diet creator Dave Asprey, Sinclair said that he takes around 500 mg of ALA every day